Mawatari Taro, Miura Hiromasa, Hamai Satoshi, Shuto Toshihide, Nakashima Yasuharu, Okazaki Ken, Kinukawa Naoko, Sakai Shuji, Hoffmann Paul F, Iwamoto Yukihide, Keaveny Tony M
Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Arthritis Rheum. 2008 Nov;58(11):3340-9. doi: 10.1002/art.23988.
Finite element analysis of clinical computed tomography (CT) scans provides a noninvasive means of assessing vertebral strength that is superior to dual x-ray absorptiometry (DXA)-measured areal bone mineral density. The present study was undertaken to compare strength changes, measured using this newer method, in rheumatoid arthritis (RA) patients who were treated with alendronate (ALN) versus those who were not.
Thirty female RA patients without radiologic signs of L3 compression fractures or a history of osteoporosis medication were enrolled in a prospective randomized clinical trial. Patients were randomly assigned to the ALN group (5 mg orally, once daily) or the control group not receiving antiresorptive treatment. All patients were evaluated by DXA and quantitative CT at baseline and reevaluated after a mean of 12.2 months. Nonlinear finite element analysis was performed on the CT scans (n = 29 available for analysis) to compute an estimate of vertebral compressive strength and to assess strength changes associated with changes in the trabecular compartment and the outer 2 mm of bone (peripheral compartment).
On average, vertebral strength was significantly decreased from baseline in the control group (n = 15) (median change -10.6%; P = 0.008) but was maintained in the ALN group (n = 14) (median change +0.4%; P = 0.55), with a significant difference between the 2 groups (P < 0.01). Strength decreased more rapidly within the trabecular bone, and ALN treatment was much more effective in the peripheral than the trabecular compartment.
Our results indicate that patients with RA can lose a substantial amount of vertebral strength over a relatively short period of time, and this loss can be prevented by ALN, primarily via its positive effect on the outer 2 mm of vertebral bone.
临床计算机断层扫描(CT)的有限元分析提供了一种评估椎体强度的非侵入性方法,该方法优于双能X线吸收法(DXA)测量的骨面积密度。本研究旨在比较使用这种新方法测量的接受阿仑膦酸盐(ALN)治疗的类风湿关节炎(RA)患者与未接受该治疗的患者的强度变化。
30名无L3压缩性骨折放射学迹象或骨质疏松症用药史的女性RA患者参加了一项前瞻性随机临床试验。患者被随机分配到ALN组(口服5毫克,每日一次)或未接受抗吸收治疗的对照组。所有患者在基线时通过DXA和定量CT进行评估,并在平均12.2个月后重新评估。对CT扫描图像(n = 29可用于分析)进行非线性有限元分析,以计算椎体抗压强度的估计值,并评估与小梁骨区域和骨外侧2毫米(外周区域)变化相关的强度变化。
平均而言,对照组(n = 15)的椎体强度从基线水平显著下降(中位数变化-10.6%;P = 0.008),而ALN组(n = 14)的椎体强度保持不变(中位数变化+0.4%;P = 0.55),两组之间存在显著差异(P < 0.01)。小梁骨内强度下降更快,ALN治疗在外周区域比在小梁骨区域更有效。
我们的结果表明,RA患者在相对较短的时间内可能会失去大量椎体强度,而ALN可以预防这种损失,主要是通过其对椎体骨外侧2毫米的积极作用。